Orphan drug approvals by the U.S. Food & Drug Administration (FDA) have increased steadily since 2010. For four of the past five years, they have comprised more than half of all drugs approved per year,. Yet, despite this, only 10 percent of the 7,000 recognized rare diseases have FDA-approved therapies. Consequently, there is relatively little research regarding some 90 … [Read more...]
The Importance of Using the Right Impact Metrics in KOL Management
The scientific landscape and the ways in which we share and view evidence continue to change at a very rapid pace. Key opinion leaders (KOLs) are interacting with and educating colleagues, patients, and the general public in new ways, and the methodologies that we use to evaluate our engagement with them have also evolved. As MSL teams -- and the levels of their visibility -- … [Read more...]
Leveraging Medical Affairs Analytics to Enhance Engagement and Demonstrate Value
In the Pharma Industry, one of the critical functions Medical Liaisons are responsible for is distilling and interpreting scientific data and communicating it to a broad audience of healthcare practitioners. Whether key opinion leaders (KOLs), payers, or policymakers, the ultimate goal is to communicate effectively to ultimately improve patient care; no one does that better! … [Read more...]